Literature DB >> 21030968

FGF23 or PTH: which comes first in CKD ?

Tamara Isakova1, Myles S Wolf.   

Abstract

In the past 40 years, disordered mineral metabolism has been among the most intensely studied areas of nephrology. A June 2010 PubMed search for 'secondary hyperparathyroidism and kidney disease' yielded 5866 references. Among these are papers documenting the development and application of numerous therapeutic agents-including calcitriol, vitamin D analogs, phosphate binders, and cinacalcet-that remain in widespread use in the day-to-day management of dialysis patients worldwide. However, almost 6000 papers later, fundamental pathophysiological concepts remain unclear, particularly regarding the early pathogenesis of disordered mineral metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21030968     DOI: 10.1038/ki.2010.281

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.

Authors:  Sigrid Lundberg; Abdul Rashid Qureshi; Sara Olivecrona; Iva Gunnarsson; Stefan H Jacobson; Tobias E Larsson
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 8.237

Review 2.  Vascular calcification: When should we interfere in chronic kidney disease patients and how?

Authors:  Usama Abdel Azim Sharaf El Din; Mona Mansour Salem; Dina Ossama Abdulazim
Journal:  World J Nephrol       Date:  2016-09-06

3.  Fibroblast Growth Factor-23 and a Vegetarian Diet.

Authors:  Shuchi Anand; Ram Jagannathan; Ruby Gupta; Sailesh Mohan; Dorairaj Prabhakaran; Myles Wolf
Journal:  J Ren Nutr       Date:  2020-04-01       Impact factor: 3.655

4.  The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients.

Authors:  Serpil Muge Deger; Yasemin Erten; Ozge Tugce Pasaoglu; Ulver Boztepe Derici; Kadriye Altok Reis; Kursad Onec; Hatice Pasaoglu
Journal:  Clin Exp Nephrol       Date:  2012-11-20       Impact factor: 2.801

Review 5.  FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.

Authors:  Daniel Edmonston; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2019-09-13       Impact factor: 28.314

Review 6.  Update on fibroblast growth factor 23 in chronic kidney disease.

Authors:  Myles Wolf
Journal:  Kidney Int       Date:  2012-05-23       Impact factor: 10.612

7.  A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model.

Authors:  Bing Dai; Valentin David; Aline Martin; Jinsong Huang; Hua Li; Yan Jiao; Weikuan Gu; L Darryl Quarles
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

8.  Evaluation of intestinal phosphate binding to improve the safety profile of oral sodium phosphate bowel cleansing.

Authors:  Stef Robijn; Benjamin A Vervaet; Patrick C D'Haese; Anja Verhulst
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

9.  "Dietaly": practical issues for the nutritional management of CKD patients in Italy.

Authors:  Claudia D'Alessandro; Giorgina Barbara Piccoli; Patrizia Calella; Giuliano Brunori; Franca Pasticci; Maria Francesca Egidi; Irene Capizzi; Vincenzo Bellizzi; Adamasco Cupisti
Journal:  BMC Nephrol       Date:  2016-07-29       Impact factor: 2.388

10.  Vitamin D deficiency aggravates chronic kidney disease progression after ischemic acute kidney injury.

Authors:  Janaína Garcia Gonçalves; Ana Carolina de Bragança; Daniele Canale; Maria Heloisa Massola Shimizu; Talita Rojas Sanches; Rosa Maria Affonso Moysés; Lúcia Andrade; Antonio Carlos Seguro; Rildo Aparecido Volpini
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.